{"Title": "Prolonged temozolomide maintenance therapy in newly diagnosed glioblastoma", "Year": 2017, "Source": "Oncologist", "Volume": "22", "Issue": 5, "Art.No": null, "PageStart": 570, "PageEnd": 575, "CitedBy": 14, "DOI": "10.1634/theoncologist.2016-0347", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019140276&origin=inward", "Abstract": "\u00a9 AlphaMed Press 2017.Background. The impact of prolonging temozolomide (TMZ) maintenance beyond six cycles in newly diagnosed glioblastoma (GBM) remains a topic of discussion. We investigated the effects of prolonged TMZ maintenance on progression-free survival (PFS) and overall survival (OS). Patients and Methods. In this retrospective single-center cohort study, we included patients with GBM who were treated with radiation therapy with concomitant and adjuvant TMZ. For analysis, patients were considered who either completed six TMZmaintenance cycles (group B), continued with TMZ therapy beyond six cycles (group C), or stopped TMZ maintenance therapy within the first six cycles (group A). Patients with progression during the first six TMZ maintenance cycles were excluded. Results. Clinical data from 107 patients were included for Kaplan-Meier analyses and 102 for Cox regressions. Median PFS times were 8.1 months (95% confidence interval [CI] 6.1-12.4) in group A, 13.7 months (95% CI 10.6-17.5) in group B, and 20.9 months (95% CI 15.2-43.5) in group C. At first progression, response rates of TMZ/lomustine rechallenge were 47% in group B and 13% in group C. Median OS times were 12.7 months (95% CI 10.3-16.8) in group A, 25.2 months (95% CI 17.7-55.5) in group B, and 28.6 months (95% CI 24.4-open) in group C. Nevertheless, multivariate Cox regression for patients in group C compared with group B that accounted for imbalances of other risk factors showed no different relative risk (RR) for OS (RR 0.77, p=.46). Conclusion. Our data do not support a general extension of TMZ maintenance therapy beyond six cycles.", "AuthorKeywords": ["Glioblastoma", "Maintenance chemotherapy", "Risk factors", "Temozolomide"], "IndexKeywords": ["Adult", "Aged", "Antineoplastic Agents, Alkylating", "Chemotherapy, Adjuvant", "Combined Modality Therapy", "Dacarbazine", "Disease-Free Survival", "Female", "Glioblastoma", "Humans", "Kaplan-Meier Estimate", "Male", "Middle Aged", "Proportional Hazards Models", "Risk Factors"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85019140276", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"6506977146": {"Name": "Skardelly M.", "AuthorID": "6506977146", "AffiliationID": "60022653, 60017246", "AffiliationName": "Center for CNS Tumors, Comprehensive Cancer Center T\u00fcbingen Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "57194194590": {"Name": "Dangel E.", "AuthorID": "57194194590", "AffiliationID": "60022653, 60017246", "AffiliationName": "Interdisciplinary Division of Neuro-Oncology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "57194183097": {"Name": "Gohde J.", "AuthorID": "57194183097", "AffiliationID": "60022653, 60017246", "AffiliationName": "Interdisciplinary Division of Neuro-Oncology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "22939169000": {"Name": "Noell S.", "AuthorID": "22939169000", "AffiliationID": "60022653, 60017246", "AffiliationName": "Interdisciplinary Division of Neuro-Oncology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "56766140100": {"Name": "Behling F.", "AuthorID": "56766140100", "AffiliationID": "60022653, 60017246", "AffiliationName": "Center for CNS Tumors, Comprehensive Cancer Center T\u00fcbingen Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "6603133544": {"Name": "Lepski G.", "AuthorID": "6603133544", "AffiliationID": "60022653, 60017246", "AffiliationName": "Interdisciplinary Division of Neuro-Oncology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "15021259200": {"Name": "Schittenhelm J.", "AuthorID": "15021259200", "AffiliationID": "60022653, 60017246", "AffiliationName": "Interdisciplinary Division of Neuro-Oncology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "14627355000": {"Name": "Bisdas S.", "AuthorID": "14627355000", "AffiliationID": "60022653, 60017246", "AffiliationName": "Interdisciplinary Division of Neuro-Oncology, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "7004867719": {"Name": "Ritz R.", "AuthorID": "7004867719", "AffiliationID": "60022653, 60017246", "AffiliationName": "Department of Neurosurgery, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "55263777100": {"Name": "Tatagiba M.", "AuthorID": "55263777100", "AffiliationID": "114705482", "AffiliationName": "German Cancer Consortium (DKTK), DKFZ partner site T\u00fcbingen"}, "8681891400": {"Name": "Tabatabai G.", "AuthorID": "8681891400", "AffiliationID": "114705482", "AffiliationName": "German Cancer Consortium (DKTK), DKFZ partner site T\u00fcbingen"}, "57191970671": {"Name": "Borchers C.", "AuthorID": "57191970671", "AffiliationID": "60022653, 60017246", "AffiliationName": "Center for CNS Tumors, Comprehensive Cancer Center T\u00fcbingen Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "57194199667": {"Name": "Koch M.", "AuthorID": "57194199667", "AffiliationID": "60022653, 60017246", "AffiliationName": "Center for CNS Tumors, Comprehensive Cancer Center T\u00fcbingen Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "7004468914": {"Name": "Paulsen F.", "AuthorID": "7004468914", "AffiliationID": "60022653, 60017246", "AffiliationName": "Center for CNS Tumors, Comprehensive Cancer Center T\u00fcbingen Stuttgart, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "6602109384": {"Name": "Zips D.", "AuthorID": "6602109384", "AffiliationID": "60017246", "AffiliationName": "Center for Personalized Medicine, Eberhard Karls University of T\u00fcbingen"}, "36143258600": {"Name": "Naumann A.", "AuthorID": "36143258600", "AffiliationID": "60022653, 60017246", "AffiliationName": "Institute of Clinical Epidemiology and Applied Biometry, University Hospital T\u00fcbingen, Eberhard Karls University T\u00fcbingen"}, "57193523558": {"Name": "Von Hehn U.", "AuthorID": "57193523558", "AffiliationID": "113865461", "AffiliationName": "Medistat GmbH"}}}